Science

Rahul Banerjee: Teclistamab and Talquetamab are approved in Mexico for triple-class exposed

Rahul Banerjee/X

Mar 4, 2025, 05:22

Rahul Banerjee: Teclistamab and Talquetamab are approved in Mexico for triple-class exposed

Rahul Banerjee, Assistant professor at Fred Hutchinson Cancer Center at the University of Washington, shared an article by Luciano J Costa, et al. on X:

“Yesterday I learned that teclistamab & talquetamab are approved in Mexico for triple-class exposed Multiple Myeloma regardless of lines of therapy Love this!

So much more practical and scientifically sound. Some day we’ll be able to ditch LOT, and it’ll be our LMIC colleagues leading the charge!”

Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma.

Authors: Luciano J Costa, et al.

Rahul Banerjee: Teclistamab and Talquetamab are approved in Mexico for triple-class exposed

cancer fight against cancer Fred Hutchinson Cancer Center Global fight against cancer LMIC Luciano J Costa Mexico multiple myeloma OncoDaily Oncology Rahul Banerjee Talquetamab teclistamab University of Washington

Senate President Passes Away After Brave Battle with Cancer: Dominick J. Ruggerio

Where to Study to Become ASCO President: 2025 Institutional Rankings

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

Dr. Don Dizon and Dr. Nathan Pennell Reflect on the Evolution of the ASCO Educational Book